Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rhabdomyosarcoma: an overview.

R Dagher1, L Helman

  • 1Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

The Oncologist
|May 25, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Prevalence of benzodiazepine use and dependence in Lebanon].

L'Encephale·2022
Same author

Nanoscale structural and electrical properties of graphene grown on AlGaN by catalyst-free chemical vapor deposition.

Nanotechnology·2020
Same author

[Attitude of psychiatrists and psychiatry residents in Lebanon towards restraint and informed consent].

L'Encephale·2020
Same author

Al<sub>5+α</sub>Si<sub>5+δ</sub>N<sub>12</sub>, a new Nitride compound.

Scientific reports·2019
Same author

Remote epitaxy using graphene enables growth of stress-free GaN.

Nanotechnology·2019
Same author

Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
Same journal

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
See all related articles

Rhabdomyosarcoma (RMS), a childhood cancer, shows improved survival for localized cases with intensive treatments. However, outcomes for metastatic rhabdomyosarcoma remain poor, highlighting the need for new therapeutic strategies.

Area of Science:

  • Pediatric Oncology
  • Cancer Biology
  • Medical Research

Background:

  • Rhabdomyosarcoma (RMS) is a rare childhood cancer originating from muscle precursor cells.
  • It is the third most common extracranial solid tumor in children.
  • RMS exhibits diverse epidemiologic, biologic, and therapeutic characteristics based on primary site.

Purpose of the Study:

  • To summarize current understanding of Rhabdomyosarcoma (RMS) epidemiology, biology, and treatment.
  • To highlight advancements in managing localized RMS.
  • To identify challenges in treating metastatic RMS.

Main Methods:

  • Review of existing literature on Rhabdomyosarcoma (RMS).
  • Analysis of treatment outcomes from large-scale international clinical trials.

Related Experiment Videos

  • Incorporation of site-based staging systems for prognosis.

    • Main Results:

    • Multimodality treatment protocols have significantly improved survival for localized RMS (60%-70% disease-free survival).
    • Common primary sites include head and neck, genitourinary tract, and extremities.
    • Prognosis is assessed using both traditional clinical grouping and a new site-based tumor-nodes-metastasis system.

    Conclusions:

    • Intensive therapies have enhanced outcomes for localized Rhabdomyosarcoma (RMS).
    • Significant challenges persist in treating patients with metastatic disease.
    • Future research should focus on developing less toxic therapies and novel approaches for metastatic RMS.